Insulet (PODD) Competitors $323.46 -5.76 (-1.75%) Closing price 04:00 PM EasternExtended Trading$323.52 +0.06 (+0.02%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PODD vs. BDX, IDXX, EW, RMD, DXCM, STE, HOLX, BAX, MASI, and GMEDShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Baxter International (BAX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry. Insulet vs. Its Competitors Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences ResMed DexCom STERIS Hologic Baxter International Masimo Globus Medical Insulet (NASDAQ:PODD) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings. Does the media refer more to PODD or BDX? In the previous week, Becton, Dickinson and Company had 14 more articles in the media than Insulet. MarketBeat recorded 36 mentions for Becton, Dickinson and Company and 22 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.28 beat Insulet's score of 1.13 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 12 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 28 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, PODD or BDX? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsulet$2.07B10.99$418.30M$3.2998.32Becton, Dickinson and Company$20.18B2.65$1.71B$5.5633.56 Is PODD or BDX more profitable? Insulet has a net margin of 10.01% compared to Becton, Dickinson and Company's net margin of 7.51%. Insulet's return on equity of 23.78% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Insulet10.01% 23.78% 9.30% Becton, Dickinson and Company 7.51%16.23%7.46% Which has more volatility & risk, PODD or BDX? Insulet has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Do insiders and institutionals hold more shares of PODD or BDX? 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate PODD or BDX? Insulet presently has a consensus price target of $352.11, suggesting a potential upside of 8.86%. Becton, Dickinson and Company has a consensus price target of $205.40, suggesting a potential upside of 10.06%. Given Becton, Dickinson and Company's higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insulet 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Becton, Dickinson and Company 0 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryInsulet beats Becton, Dickinson and Company on 10 of the 17 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.17B$11.18B$6.19B$10.60BDividend YieldN/A1.87%5.72%4.86%P/E Ratio98.3214.3221.1124.06Price / Sales10.9926.52577.46128.87Price / Cash74.2124.6936.5560.64Price / Book18.733.4812.076.53Net Income$418.30M$210.63M$3.32B$276.75M7 Day Performance2.27%-0.92%-0.16%0.20%1 Month Performance-1.32%0.03%5.76%1.67%1 Year Performance37.74%-8.18%65.71%32.73% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.6642 of 5 stars$323.46-1.7%$352.11+8.9%+39.1%$23.17B$2.07B98.323,900Positive NewsAnalyst ForecastBDXBecton, Dickinson and Company4.945 of 5 stars$186.76+0.1%$205.40+10.0%-21.5%$53.47B$20.18B33.5974,000Positive NewsIDXXIDEXX Laboratories4.4426 of 5 stars$633.32+2.8%$656.50+3.7%+37.3%$49.29B$3.90B52.7311,000Positive NewsEWEdwards Lifesciences4.509 of 5 stars$72.94-1.4%$87.06+19.4%+10.8%$43.41B$5.44B10.4915,800Upcoming EarningsOptions VolumeRMDResMed4.551 of 5 stars$273.10+0.4%$292.91+7.3%+11.0%$39.70B$5.15B28.7210,600Positive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionDXCMDexCom4.8291 of 5 stars$65.20+0.1%$97.42+49.4%-3.3%$25.54B$4.03B45.2810,300Upcoming EarningsAnalyst ForecastSTESTERIS4.8575 of 5 stars$235.65-0.1%$273.50+16.1%+9.4%$23.23B$5.46B36.0917,787Positive NewsAnalyst RevisionHOLXHologic4.4879 of 5 stars$65.51-3.3%$80.15+22.4%-9.4%$15.07B$4.03B27.187,063Trending NewsAnalyst ForecastInsider TradeBAXBaxter International4.594 of 5 stars$22.10+0.7%$28.89+30.7%-37.4%$11.27B$10.64B-73.6538,000Trending NewsUpcoming EarningsMASIMasimo4.4541 of 5 stars$148.01+2.3%$194.60+31.5%+2.4%$7.86B$2.09B-17.375,600GMEDGlobus Medical4.8539 of 5 stars$57.53+1.7%$87.27+51.7%-15.0%$7.64B$2.52B22.135,300Positive News Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives IDEXX Laboratories Alternatives Edwards Lifesciences Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Hologic Alternatives Baxter International Alternatives Masimo Alternatives Globus Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.